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ABSTRACT
The discovery of new pharmacologic targets is important for the advancement of
pharmacotherapy and identification of new indications for current drugs. The aryl
hydrocarbon receptor (AHR) is a physiologic sensor of both chemical environmental
pollutants and ligands of natural origin. Given the broad spectrum of ligands that activate
the AHR and its relationship with toxicology, the AHR is not thought to be a traditional
target for pharmacotherapy. However, multiple studies have shown potential for the AHR
as a novel pharmacologic target Therefore, identifying less toxic agents that modulate the
AHR may elucidate mechanisms for pharmacological targeting of the AHR. The
hypothesis addressed for this thesis project is that chemical libraries of established drugs
can be used to map the pharmacological space of the aryl hydrocarbon receptor. Three
specific aims are proposed to address this hypothesis. Specific aim 1: Develop a high
v

throughput screening assay to identify established drugs that activate the AHR. Specific
aim 2: Use a chemical library of known pharmacologically active agents to map
pharmacological space of the AHR and identify a lead compound for further evaluation.
Specific aim 3: Determine chemical structure activity relationship of the lead compound’s
pharmacophores and AHR activation potency. The AHR assay developed for Aim 1
incorporated an AHR-responsive green fluorescence protein (GFP) reporter that could be
transduced into any cell type of interest. For normalization of transduction efficiency, a
dtTomato expressing vector was optimized for expression without interference of the GFP
reporter. Both the human colon cancer cell line Caco2 and the liver cancer cell line HepG2
were used in these studies. Drug screening for AHR activation using the AHR assay
resulted in the identification multiple ligands including a lead compound. The lead
compound in this study used for further evaluation was alpha-tocopherylquinone (TQ). The
quinone structure is a critical component of TQ, interestingly other AHR ligands have been
found to have a quinone structure as a molecular component. (eg dioxin) However, quinone
structure ability to activate the AHR is less defined compared to other compounds like
polycyclic carbons. In this study, differences were observed in the toxicity and AHR
activation profile of fully substituted and unsubstituted para-quinones. The findings from
these experiments suggest that there is a direct relationship between the number of carbon
substitutions and the potency of the para-quinone to elicit an effect on the AHR. For
example, we found that benzoquinone (BQ), an unsubstituted para-quinone was a relatively
potent ligand of the AHR. Furthermore, adding a single methyl group to the benzoquinone
increased its potency to activate the AHR. However, further methyl substitutions to the
para-quinone ring diminished the para-quinone potency to activate the AHR. A compound
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that supported this observation was duroquinone, a fully substituted para-quinone which
showed no AHR activity in the AHR assay. This study identifies critical characteristics
necessary for para-quinones to activate the AHR and gives rise to a new class of
compounds with potential of becoming novel treatments for disease through AHR
activation.
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CHAPTER 1: INTRODUCTION
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Introduction Summary
The process of drug discovery and development often starts with the identification
of a target that has an association or contribution to disease progression; such as a gene, a
protein, or a receptor (Li and Corey, 2013). After target identification, it is important to
assess whether or not modulating the target has a therapeutic effect. Equally important, is
the identification of modulators for the target and evaluation of the characteristics linked
with the modulators potency. Given that the outcome of modulating the target with a less
toxic agent is therapeutic, the target can then serve as a pharmacological target with the
potential to treat disease. The discovery of new pharmacologic targets is important for the
advancement of pharmacotherapies with novel mechanisms of action. Discovering new
pharmacologic targets becomes especially important in diseases with a broad involvement
of different proteins, physiological pathways and signaling such as immune mediated
inflammatory diseases.
The Aryl Hydrocarbon Receptor (AHR) is an emerging target which shows promise
in becoming a pharmacologic target for treating disease. The AHR for many years was
extensively studied by the toxicology field for its major role in mediating the responses to
a broad scope of xenobiotics and environmental pollutants such as polycyclic aromatic
hydrocarbons and polychlorinated biphenyls. Nonetheless, the AHR has recently enticed
the attention of immunologists due to its extensive expression in the immune system and
its involvement in important physiological pathways such as inflammation (Stockinger et
al., 2014). AHR involvement in inflammation, has illustrated the potential for the AHR as
a novel pharmacological target for the treatment of diseases with inflammatory pathways,
e.g. inflammatory bowel disease.
2

The AHR may be a feasible target for the treatment of inflammation in
inflammatory bowel disease because it may provide more selective treatment with less side
effects compared to the anti-inflammatory methods currently employed to treat
inflammatory bowel disease (Ehrlich and Kerkvliet, 2017). However, there are several
factors complicating the pharmacological considerations for the AHR. For example, there
are many different ligands known to activate the AHR. That is, the AHR can be activated
by a wide array of chemically diverse structures. Since activation of the AHR is mediated
by many different ligands, it is challenging to precisely understand the structure and
chemical properties required for AHR ligands. Another factor that complicates
pharmacological considerations of the AHR is the fact that most AHR ligands studied to
date are toxins, and they do not possess acceptable characteristics as pharmaceutically
acceptable targets. Hence, the AHR historically has been considered important as a
mediator toxicological action. Based on these considerations, an area of interest addressed
in this thesis is to elucidate characteristics necessary for less toxic chemical functional
groups to activate the AHR.
In the interest of finding less toxic chemical functional groups to act as AHR
ligands, a drug screening assay of an augmented version of the Prestwick Chemical Library
was developed (It was an augmented version of the Prestwick Library due to the inclusion
of para-quinones). This presented a very attractive opportunity since the AHR appears to
have low selectivity for ligands. Hence, it was expected for the AHR to have multiple
unknown ligands already on the market Furthermore, the drugs used in these efforts have
already proven to be effective in pharmacological action; safe and extensive information is
available based on their prior use. Following the results of the augmented Prestwick library
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screening, a group of compounds was chosen for further evaluation of the functional groups
responsible for each compound’s potency.
A few “hits” were identified resulting from the drug screening including quinones,
which we decided to focus further studies. Due to the fact that they are derivatives of
aromatic compounds which are seen extensively in pharmaceutical drugs and their activity
to modulate the AHR has not been profoundly investigated. The results from the studies
completed in this thesis may provide better understanding of the ligands that activate the
AHR and the chemical characteristics required in quinone structures to modulate their
potency to activate the AHR.
Aryl Hydrocarbon Receptor Biology
The AHR is a ligand activated transcription factor, a member of the basic helixloop-helix (bHLH-PAS) transcription factors, and is expressed broadly in the body. For
example, the AHR without the presence of a ligand is present in the cytoplasm bound to
actin filaments as an inactive complex with several chaperone proteins, including HSP90,
AIP, and p23 (Stockinger et al., 2014). When a ligand binds to the AHR, the complex
detaches from the actin filament and translocates into the nucleus, where it is released from
the complex, heterodimerizes with the aryl hydrocarbon receptor nuclear translocator
protein (ARNT; a.k.a. HIF-1beta) and then binds to the region of the genome containing
its binding motif, the dioxin response element (DRE), also referred to as the xenobiotic
response element (XRE). After the AHR:ARNT complex binds to the DRE, it modulates
the transcription of genes such as CYP1A1, CYP1A2, CYP1B1, and the AHR repressor
(AHRR). The signaling of the AHR is regulated at three levels: AHR protein degradation,
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ligand metabolism by CYP1A1, and disruption of the AHR/ARNT complex by AHRR.
(Stockinger et al., 2014).

Figure 1. Illustration of the mechanism of ligand activated aryl hydrocarbon receptor
activation (from Stockinger et al., 2014).
Aryl Hydrocarbon Receptor Background and Function
The AHR was first discovered and investigated because of its recognition as
mediator of the toxicity of 2,3,7,8-tetrachlorodibenzodioxin (TCDD) (Stockinger et al.,
2014). TCDD is a chemical produced as a side product of industrial organic synthesis of
herbicides as well as used as a defoliant in the Vietnam War, known as the Agent Orange.
It was also responsible for toxicities associated with the Seveso disaster in Milan, Italy in
1976. The Seveso disaster was an industrial accident that resulted in the highest known
5

exposure of TCDD in residential populations, which gave rise to numerous scientific
studies and standardized industrial safety regulations (Pesatori et al., 2003). TCDD was
found to cause chloracne in addition to life-threatening clinical complications such as
progressive liver failure, emphysema, renal failure, and myocardial degeneration
(Stockinger et al., 2014)
Ongoing research revealed that the AHR was not a specific receptor for TCDD. As
a matter of fact, AHR mediates many responses to a broad scope of xenobiotics and
environmental pollutants, such as polycyclic aromatic hydrocarbons and polychlorinated
biphenyls (Vondracek et al., 2004). These environmental pollutants promote a number of
toxic and carcinogenic responses in animals and humans when they activate the AHR.
Activation of the AHR upregulates the transcription of many detoxification genes,
including those coding for the Phase I xenobiotic-metabolizing cytochrome P450 enzymes
CYP1A1, CYP1A2, CYP1B1, and CYP2S1, and the phase II enzymes UDP-glucuronosyl
transferase UGT1A6, NAD(P)H-dependent quinone, oxydoreductase-1 NQO1, the
aldehyde dehydrogenase ALDH3A1, and several glutathione-S-transferases (Vondracek et
al., 2004).
Conversely, evidence from AHR knockout mice reveals that the AHR has functions
independent of toxicity and detoxification of harmful xenobiotics. Absence of the AHR in
AHR-null mice gives rise to cardiovascular disease, hepatic fibrosis, reduced liver size,
spleen T-cell deficiency, dermal fibrosis, liver retinoid accumulation and shortening of life
span (Puga et al., 2010). Likewise, there have been multiple studies that have specifically
studied the involvement of the AHR with different physiological responses, including
inflammatory pathways (Murray et al., 2017), (Benson and Shepherd, 2011), (Wang et al.,
6

2017). Owing to the involvement of the AHR with many different physiological responses
as seen by these studies, the AHR becomes an attractive and innovative target for the
advancement of pharmacotherapy.
The Role of Aryl Hydrocarbon Receptor in Inflammatory Pathways
Activation of the AHR has been linked with either enhancement or repression of
inflammatory signaling. However, in the gastrointestinal tract, most studies support that
the activation of the AHR by a ligand produces an anti-inflammatory outcome (Murray et
al., 2017). One of the studies that furthers explores this concept is the study published by
Jenna M. Benson and David M. Shepherd from the University of Montana (Benson and
Shepherd, 2011). In their study, it was found that AHR activation by TCDD reduced the
inflammation associated with Crohn’s disease. Mice were gavaged with TCDD prior to
presensitization and colitis induction. After TCDD exposure, colitis was induced via an
intrarectal instillation of 2,4,6-trinitrobenzenesulfonic acid (TNBS). Following TCDD
exposure and colitis induction, body weight loss and the severity of clinical symptoms was
evaluated (overall body condition, stool consistency, and dehydrationstate via a skin pinch
test) and the severity of each clinical sign was also scored. These investigators observed
that mice without TCDD exposure lost approximately 17% of their initial body weight
following TNBS exposure and did not recover by the end of the study. In contrast, TCDDexposed mice lost only 8% of their initial weights and recovered weight rapidly.
Also, a protective effect of TCDD in the clinical severity of colitis was observed,
as seen by stool consistency, dehydration, and body condition. Lastly, Benson and
Shepherd (2011) looked at the difference in inflammation between the mice and the
difference in gene expression in order to assess if there was a correlation between the AHR
7

and TCDD mediated improvement of colitis. Inflammation was significantly reduced in
the mice treated with TCDD. With respect to gene expression, they reported an
upregulation in the expression of Cyp1A1, which was a significant finding in their study
as CYP1A1 is a well-established marker of AHR activation. An additional study that
illustrates the use of the AHR as a pharmacologic target for the treatment of gastrointestinal
inflammation was published by Wang and Yang (2017). In this study, the potential of the
AHR to attenuate colon inflammation in mice was investigated. To accomplish this, a
group of mice that expressed the AHR and another group of mice with an AHR knockout
were used. Colitis was induced in both mouse groups by administering 3% dextran sulfate
sodium (DSS) for 7 days. Both groups were also administered 6-formylindolo(3,2-b)
carbazole (FICZ), a well-established activator of the AHR (Jönsson et al., 2009); starting
2 days after the administration of DSS. The results from this study indicated that the
injection of mice with FICZ in the AHR group significantly attenuated DSS-induced colitis
and decreased the expression levels of inflammatory cytokines and AHR expression was
upregulated. In addition, the mice with the AHR knockout exhibited elevated inflammatory
cytokine production and developed more severe colitis. (Wang et al., 2017). The findings
from both the Benson and Wang studies further support the AHR as a pharmacological
target for the treatment of disease, at least for inflammatory pathways such as inflammatory
bowel disease.
Potential of the Aryl Hydrocarbon Receptor as a Pharmacologic Target
Studies examining the relationship between the AHR and the immune system have
identified unique characteristics that may improve the safety profile when compared with
other immunosuppressant drugs. Given the fact that memory responses are less sensitive
8

to immune suppression by AHR activation than primary immune responses suggests that
activating the AHR by a ligand may not interfere with the established immunity. (Ehrlich
and Kerkvliet, 2017). These findings, in conjunction with the attenuation of inflammation
in colitis after AHR activation seen in the gastrointestinal studies of Benson and Wang
increases the likelihood of the AHR for use as a target for pharmacotherapy; as these
findings highlight the therapeutic effect following AHR activation. Given the connection
between the AHR and toxic pollutants, it is thought that activators of the AHR are toxic,
which gives rise to hesitation regarding the use of ligands to activate the AHR for
pharmacotherapy. Therefore, it is crucial to expand our knowledge of AHR ligands as well
as their toxicity in order to be able to use the AHR as a pharmacologic target.
In an effort to increase our understanding of AHR ligands and their toxicity,
multiple studies have screened drugs for AHR activity and have successfully found less
toxic AHR activators. A large scale screening of 596 compounds in vivo assessed the
induction of CYP1A1 and other AHR related genes in liver, kidney, and heart (Hu et al.,
2007). From the screening a subset of 147 compounds, they were then evaluated in vitro
for their ability to activate the AHR using a combination of gel shift, reporter gene, and
competitive reporter binding assays. The combination of the in vivo and in vitro studies
identified nine AHR agonists of which six were marketed FDA approved drugs. The FDA
approved compounds identified were flutamide, leflunomide, nimodipine, omeprazole,
sulindac, and raloxifene (Hu et al., 2007). From these six drugs none of them produced
dioxin-like toxicity in rats or humans. The findings from this study and others have not
only shown that AHR activation does not always result in dioxin-like toxicity but also
illustrates the lack of selectivity of the AHR has for ligands.
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Drug Repurposing
Given the fact that the AHR is activated by many different compounds which may
include currently marketed FDA-approved drugs, there is a high probability of being able
to repurpose an off-patent FDA approved drug for therapeutic activation of the AHR. The
concept of drug repurposing is the application of known drugs and chemical compounds to
treat new indications in addition to the indications they had when they first came out to the
market (Oprea et al., 2011). Drug repurposing has seen an increase in potential since there
has been a reduction in the number of new drugs reaching the market due to the high costs
of development and low approval odds for drugs (Oprea et al., 2016). On the other hand,
the cost of repurposing drugs is significantly lower and the probability of success is higher
due to the fact that the drugs have already been on the market and an extensive database
for their safety, pharmacokinetics and pharmacodynamics. Besides pharmaceutical
industries turning their attention to drug repurposing, academia and small business research
efforts have played an increasing role in drug discovery, with drug repurposing as one of
the majors areas of activity (Oprea et al., 2016). As a means of repurposing drugs for AHR
therapeutic activation, for this study, an AHR reporter assay was developed to screen the
Prestwick library, a chemical library of 1,280 off-patent drugs.
Alpha-tocopherylquinone (TQ) was identified as a lead compound for activation of
the AHR with strong pharmacotherapeutic potential. TQ was a very interesting finding
since it was speculated that most AHR ligands had to have a polycyclic component in their
structure in order to activate the AHR. Quinone structures on the contrary have not been
extensively evaluated for their use as AHR ligands. Given the novelty of these findings,
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we further investigated quinone structures and their potential to become pharmacologic
activators of the AHR.
Quinones
Quinones are derived from aromatic compounds, such as benzene and naphthalene,
by conversion of an even number of –CH= groups into –C(=O)– groups with any necessary
rearrangement of double bonds, resulting in a fully conjugated cyclic dione structure
(Bolton et al., 2014). This quinone formation is illustrated in Figure 2.
Figure 2.

(Bolton et al., 2016)
Figure 2. Example of metabolic pathways converting aromatic compounds to quinones.
Quinone structures and derivatives are relevant in biology due to their prevalence
in foods and in different biological pathways. For instance, the quinone vitamin K has been
directly involved in the regulation of blood clotting. Other quinones like TQ, the oxidation
product of vitamin E, has been shown to be involved in oxidation-reduction reactions
(Infante et al., 1999). Additionally, flavonoids and flavonoids which are antioxidants
11

commonly found in foods, are also quinones. In the pursuit of elucidating the
characteristics necessary for quinones to activate the AHR, 1,4 cyclohexanedione a
“simple” quinone was picked and its ability to modulate the AHR was compared to
quinones with the same backbone structure, but different substitutions on the carbons as
seen on the following table.
Table 1. Quinone structures investigated in this study.

1,4 Cyclohexanedione

Benzoquinone

Methyl-p-benzoquinone

12

2,6-Dimethylbenzoquinone

2,5-Dimethyl-1,4-benzoquinone

Trimethylbenzoquinone

Duroquinone

2-tert-Butyl-1,4-benzoquinone

Background Research from the Thompson Laboratory
Dr. Thompson’s laboratory performed microarray studies with prostate cancer cells
using Affymetrix Human Genome U1333A. Plus 2.0 GeneChip arrays to examine
alterations in gene expression induced by TQ. These findings showed that a high ranked
pathway modulated by TQ included xenobiotic metabolism pathways. An increase in phase
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I and II metabolizing enzymes such as CYP 1A1, aldoketoreductase 1C1, AKR1B10,
glutamate-cysteine ligase, and AHR expression was observed as shown in the following
table.
Table 2. Messenger RNAs induced by TQ

Additional studies performed in the Thompson laboratory observed activation of
an XRE/DRE luciferase reporter with TQ, but not VE (Figure 3). Lastly she also performed
experiments were she used siRNA for AHR to knockdown AHR expression in LNCaP
prostate cells to see if AHR mRNA and CYP 1A1 mRNA levels were dependent to AHR
activation by TQ (Figures 1b,1c, and 1d).
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Figure 3. A. Activation of an XRE/DRE luciferase reporter was observed with TQ, but
not VE. B. siRNA against AHR was used to knockdown AHR protein expression (NC =
scrambled negative control). C. & D. AHR RNAi experiments to determine the
modulation of AHR. C. and CYP1A1. D. gene expression by TQ treatment at 48 and 96 h
after treatment. Quantitative PCR was used to measure AHR and CYP1A1 mRNA levels.
To further confirm the activation of the AHR by TQ mouse embryonic fibroblasts
(MEFs) were acquired from AHR knockout mice, mice hemizygous for the AHR, and
wild-type mice. The heterozygous and knockout MEFs were treated with vitamin E (VE),
TQ, and benzo(a)pyrene (BaP); and CYP1A1 induction was measured 4 d after treatment.
The wild-type and knockout MEFs were treated with tert-butylquinone (tBQ),
pentamethylchromanol (PMCol), and TQ for 4 d. CYP1A1 mRNA levels were measured
15

as a marker of AHR activation. The results from this experiment showed a significant
increase on the levels of CYP1A1 mRNA which was found intriguing as the structure of
tBQ and TQ do not resemble the typical dioxin like structure which is thought to be
responsible for AHR activation.

B

A
*
Relative CYP1A1 mRNA (Fold Increase  SD)

Relative CYP1A1 mRNA (Fold Increase  SD)

*
*

Control

VE

TQ

BaP

*

Control

tBQ

PMCol

TQ

Figure 4. A. Heterozygous and knockout MEFs were treated with vitamin E (VE), TQ,
and benzo(a)pyrene (BaP); and CYP1A1 induction was measured 4 d after treatment. B.
Wild-type and knockout MEFs were treated with tert-butylquinone (tBQ),
pentamethylchromanol (PMCol), and TQ for 4 d. CYP1A1 mRNA levels were measured
as a marker of AHR activation. (*P<0.05).

Rationale for Investigating Quinones
Quinones structures like tBQ, which were unanticipated chemical structures to be
activators of the AHR, were identified as activators of the AHR, which in turn increases
the scope of chemical structures recognized to activate the AHR. Although our results
further support that the AHR is not highly selective, unique structure-activity relationships
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were found that will assist identifying AHR pharmacophores. From the compounds
investigated in addition to the Prestwick Chemical Library, tBQ was found to be an
activator of the AHR while duroquinone showed no AHR activity.
Considering the results observed from this augmented Prestwick Library screen
and the previous studies performed in the Thompson laboratory, it was decided to further
evaluate quinone structures by validating their interaction with the AHR and their
potency to activate it. The main question addressed was if the number of substituted
carbons available in the quinone structure had a relationship with the potency of the
quinone structure to activate the AHR. From the findings during the Prestwick Library
screening we propose that increasing the number of substitutions will in turn decrease the
molecule’s potency to activate the AHR. The molecules deemed appropriate to address
this question was duroquinone, 2,3-dimethoxy-6-methyl- 1,4 benzoquinone, 2,5 dimethyl
benzoquinone, 2,6-dimethylquinone, tertbutyl-benzoquinone, methylbenzoquinone,
benzoquinone and 1,4 cyclohexandione (Figure 5).
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Figure 5. Quinone and related compounds analyzed for AHR activation using the AHRA
assay based on the lead compound, tocopherylquinone (TQ).

Thesis Objectives:
1. Characterize the chemical functional groups necessary for less toxic compounds to
act as AHR ligands.
2. Evaluate which attributes of functional groups determine the potency for activating
the AHR.
3. Increase the number of known ligands of the AHR.
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CHAPTER 2: DIFFERENTIAL ARYL HYDROCARBON
RECEPTOR ACTIVATION BY SUBSTITUTED QUINONES
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Abstract
The aryl hydrocarbon receptor (AHR) is a polyfunctional, ligand activated
transcription factor that serves as a sensor for environmental toxicants. Physiological
actions of the AHR, such as activity in inflammation, support ongoing efforts to identify
pharmacological modulators of the AHR (Ehrlich and Kerkvliet, 2017). In an effort to
identify drug-like modulators of the AHR, an AHR reporter assay was developed. The
pMMTVdsEGFP vector was modified to be AHR responsive via the incorporation of a
dioxin response element into the MMTV promoter. Caco2 or HepG2 cells expressing a
green fluorescence protein (GFP) based reporter sensitive were used to assess AHR
activation. Cells stimulated by AHR activation express GFP, which can readily be
quantified as the number of GFP positive cells, was found to be dependent on the potency
of the ligand used to activate the AHR. This novel method is referred to as the Aryl
Hydrocarbon Receptor Activation (AHRA) assay. The AHRA assay was originally
validated using a FICZ dose-response with a Z factor of 0.28 achieved in Caco2 cells and
0.52 in HepG2 cells. In addition to screening the Prestwick Chemical Library, a library of
1,280 small molecules, most of which are agency approved, a collection of quinone
containing compounds was also screened. From these screens, 8 off-patent drugs were
identified from the Prestwick Chemical Library. In addition, the oxidation product of
vitamin E, tocopherylquinone (TQ), was found to activate the AHR. TQ has a quinone
functional group, which was chosen as a lead functional group for detailed investigation.
AHRA assay analysis of para-quinones containing different numbers of methyl
substitutions were screened. Para-quinone itself was found to be a relatively potent
activator of the AHR. A single methyl or butyl substitution to one of the carbons present
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in the para-quinone structure increased the efficiency of AHR activation. However,
additional substitutions decreased potency of AHR activation. Increased toxicity with two
or three additional substitutions. However, the fully methyl substituted quinone,
duroquinone, did not activate the AHR, even at high concentrations and had reduced
toxicity compared to other quinones with zero to three substitutions. This finding is
enigmatic in that the quinone structure of TQ is fully substituted. Independent of this
unexpected finding, it was observed that quinone structures containing a single
substitution may serve as useful functional groups in the design of novel AHR activators
with therapeutic potential.

Introduction
The aryl hydrocarbon receptor (AHR) was first identified as a mediator of TCDD
toxicity, a contaminant of the herbicide Agent Orange (Sorg O et al., 2014). Since then,
many different natural and synthetic environmental toxicants have been identified as
ligands for activating the AHR. AHR activation by these agents results in the induction of
genes associated with xenobiotic metabolism (Vondracek et al., 2004). Thus, the AHR
has for many years been considered to have a key role in serving as a sensor of exposure
to environmental toxicants. More recently, potent AHR ligands of endogenous origin
have been identified. Also, modulation of AHR activity has been shown as useful in the
treatment of models of inflammation, such as chemically induced colitis (Ehrlich and
Kerkvliet, 2017; Benson and Shepherd, 2011). However, ligands used for this purpose
have established toxicities or are not otherwise recognized as safe for human use. A key
purpose of this study is to identify drugs that activate the AHR with established value for
use in humans.
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The AHR is a ligand-activated basic helix-loop-helix transcription factor (Stockinger et
al., 2014). Once activated, the AHR sheds chaperone proteins that help stabilize it in the
uninduced state in the cytoplasm and it then translocates to the nucleus where
heterodimerization occurs with its binding partner the Aryl Hydrocarbon Receptor
Nuclear Translocator (ARNT) protein (Stockinger et al., 2014). ARNT is also a binding
partner for HIF-1alpha where it was independently designated HIF-1beta. Though
activation of the AHR is primarily associated with xenobiotic metabolizing enzymes,
AHR activation has also been associated with actions in differentiation, adaptive and
innate immune responses, and organ homeostasis (Roman et al., 2017). Thus, the AHR
may serve as a pleiotropic mediator of cellular responses. Recently, additional proteinprotein interactions have been identified for the AHR, which may enable unique celldependent responses of the AHR.
Recently, encouraging breakthroughs in utilizing old drugs for new uses have
been reported (Sachs et al., 2017). This so called “drug repurposing” has allowed
transitioning the use of a drug originally designated for use against a specific disease state
to find additional utility in treatment of an entirely distinct disease state, where its action
was not historically recognized as relevant. In fact, small molecule chemical libraries of
such drugs have facilitated this effort, where high-throughput analysis of specific
molecular or cellular responses can be facilitated. One such example is the Prestwick
Chemical Library, which contains 1,280 small molecules of mostly off-patent drugs. In
this study, a novel method that allows for high-throughput analysis of AHR activation
was developed to allow screening the Prestwick Chemical Library in addition to other
potential useful agents for repurposing.
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The development of high-throughput methods for drug screening has greatly
facilitated efforts in drug repurposing. Assays developed should provide an accurate
assessment of key pathways associated with a pathological conditions meaningful for
drug repurposing. Optimally, the assay would be sufficiently sensitive and robust to
allow for screening of agents with high specificity of drug action. Cell based assays often
have many favorable screening characteristics. For example, a favorable feature for cellbased assays is that they allow the screening of agents that alter ligand binding to
transcription factors for alterations in transcriptional activation mediated by the ligand.
This property is favorable compared to ligand binding assays, which, although they
provide information on the ligand affinity for the receptor, they do not enable an
understanding of how ligand binding modulates the transcriptional activity of the
receptor. However, cell based assays typically do not allow for identifying a single action
without the potential for off-target effects. For many cell based assays, it is critical to
integrate additional assays for specificity of action and validation of on-target effects. In
this study, a flexible cell-based assay was developed to screen for drugs that activate the
AHR and was designated, the “Aryl Hydrocarbon Receptor Activation” (AHRA) assay.

Materials and Methods
Chemicals
The Prestwick Chemical Library, a chemical library of 1,280 small molecules,
mostly off-patent, approved drugs (e.g., FDA), was obtained from Prestwick Chemical
(Illkirch, France). Vitamin E as dl--tocopherol and most other chemicals were obtained
from Millipore Sigma (St. Louis, MO), unless specified otherwise. 2,3,5-trimethyl-1,4-
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benzoquinone was obtained from Manchester Organics (Runcorn, Cheshire, UK). dl-tocopherylquinone was obtained from Research Organics (Cleveland, OH).
Expression Vectors
To construct pTBXMG, the mouse Cyp1A1 DRE region as used to construct
pMpap1.1 (El-Fouly et al., 1994) was cloned by PCR and subcloned into
pMMTVdsEGFP (Thompson et al., 1993). To determine specificity of DRE driven
responses using pTBXMG, the pMMTVdsEGFP vector was used in place of pTBXMG.
The pCSCMVdtTomato vector was used for transfection normalization as specified
below.
Cell Culture and Transfection
Caco2 human colon adenocarcinoma cells and HepG2 human hepatocellular
carcinoma cells (ATCC, Manassas, VA). Caco2 cells were maintained in Eagle’s
Minimal Essential Medium (EMEM) + 15% fetal bovine serum (FBS, Invitrogen,
Carlsbad, CA), and 1% penicillin/ streptomycin. For Caco2 cells electroporation buffer
was put in the hood an allowed to reach room temperature before use electroporation.
Caco2 cells were transferred to a 15 ml sterile polypropylene tube and centrifuged for 5
minutes at 800-1000 rpm for 5 minutes. After centrifugation the cells were resuspended
in 400 uL of electroporation buffer and 20 ug of the plasmid pTBXMG plasmid was
added. The cells were then mixed and transferred to an electroporation cuvette to undergo
electroporation. The optimal settings for electroporation were voltage 250V, mode 1V,
and pulse 10ms, number of pulses 1, with unipolar polarity. After electroporation cells
were resuspended in 12 mL of Caco2 media and transferred to a 96 well plate. Cells were
incubated for 24 hours before Prestwick Library treatment. HepG2 cells were maintained
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in Minimal Essential Medium (MEM) + 10% fetal bovine serum (FBS, Invitrogen,
Carlsbad, CA), and 1% penicillin/streptomycin. For the Aryl Hydrocarbon Receptor
Assay (AHRA), HepG2 cells were plated 24 h prior to transfection in 96-well flatbottomed tissue culture plates at 12,500 cells per well. Cells were transfected with
pTBXMG and pCSCMVtdTomato (Addgene) at a ratio of 1:100, respectively, using
FuGENE 6 according to the manufacturers’ instructions (Promega, Madison, WI). To test
for non-specific MMTV promoter activation (i.e., not mediated by the AR), cells were
transfected with pMMTVdsEGFP (Thompson et al., 1993) in place of pTBXMG using
FuGENE 6, as described above. Treatments were administered 24 h after transfection.
Chemicals from the Prestwick Chemical Library were screened at a final concentration of
10 M. All other AHRA chemical screening used concentrations, as specified.
EGFP Reporter Assay Validation
In order to evaluate pTBXMG as a reporter of AHR activation a dose response
with 6-Formylindolo [3,2-b] carbazole (FICZ) was performed. FICZ is a well-established
potent activator of the AHR. Thus, pTBXMG transfected cells treated with FICZ are
expected to emit green fluorescent signal with an increasing signal as the dose of FICZ is
increased. On the contrary, cells treated with FICZ vehicle control are not expected to
emit green fluorescent signal. The dose-response was from 0 to 100 nM. Maximal FICZ
response occurred at 10 nM (Fig.2). With toxicity observed at higher doses. Hence, we
established that the optimal dose for FICZ as a positive control was 10nm which was
used in the sub sequential analysis.
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Cell Growth and Viability Analyses
Relative cell viability changes were determined using LNCaP and LAPC4 cells
plated in 12-well tissue culture plates. Cell viability was determined by trypan blue dye
(0.4%; Sigma, St. Louis, MO) exclusion determined by cell count using a hemacytometer
and light microscopy. Cell growth analysis were performed using DU145, LNCaP, and
LAPC4 cells plated in 96-well tissue culture plates. Relative cell numbers with and
without TQ and VE treatment were determined using the CyQUANT NF Cell
Proliferation Assay Kit (Invitrogen), according to kit instructions.
Microscopic Analyses and AHRA Quantification
Both light and fluorescent microscopy was performed using an Olympus IX70
Inverted Fluorescent Microscope equipped with an Olympus DP72 camera. Olympus
cellSens Dimension 1.13 Life Science Imaging Software (Olympus, Waltham, MA) was
used for image capture. To quantify the AHRA, the number of GFP positive cells
(excitation at 488 nm) were visually quantified in a vertical scan through each well of a
96-well plate using a 10 objective and 10 eyepiece with an overall magnification of
100.
Statistical Analyses
Significant differences in values between groups were assessed using an unpaired
t-test with SigmaStat 3.1 software (Systat Software, Inc., San Jose, CA). P values less
than 0.05 were used to signify statistical significance. Studies were performed as
specified with a minimum of 3 samples (i.e., n 3).
28

Results
Aryl Hydrocarbon Receptor Activation Assay
Studies were performed to evaluate the ability of small molecules to activate the
AHR. Initially, a small molecule screening assay was developed by producing a green
fluorescence reporter vector driven by an AHR responsive promoter (Figure 1).

Figure 1. Development of the Aryl Hydrocarbon Receptor Activation (AHRA) assay for
high throughput screening of AHR activation. A. Construction of an AHR responsive
reporter vector pTBXMG was used to screen for AHR activation used for Aryl
Hydrocarbon Receptor Activation (AHRA) assay development. B. Sequence of actions
for performing the AHRA assay. C. Photomicrograph of GFP positive cells (blue arrow)
showing cells with significant AHR activation. Red arrow shows a tdTomato positive cell
used for normalization of transfection (100).
The next series of studies were performed to validate the activity of the AHRA
assay.
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Figure 2. Assays used to examine AHR activation. A. FICZ dose-response curve using
the AHRA assay in Caco2 cells. B. Kinetic analysis of AHRA assay efficiency at 15, 20,
25, and 45 h after treatment with a dose-response to FICZ in Caco2 cells. C. AHRA assay
for analysis of TQ AHR activation in Caco2 cells (*P<0.05). D. Validation of TQ AHR
response using the pGudLuc6.1 vector for analysis of AHR activation in LNCaP human
prostate cancer cells. Luciferase is the reporter for this assay (*P<0.05).
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Prestwick Library Analysis

Figure 3. Results from the Prestwick Chemical Library Screen using the AHRA assay in
Caco2 cells. Each plate represents the analysis of 320 compounds for a total of 1,280
compounds analyzed. Threshold cut off is based on the FICZ positive control (not shown
due to scale distortion) and background levels of activity. A. For Plate 1, the threshold
was set at 3; P1E4 and P1L8 gave above threshold values. B. For Plate 2, P2D14 and
P2O12 gave above threshold values. C. For Plate 3, the threshold was set at 3; P3B4 and
P3O10 gave values above threshold. D. For Plate 4, the threshold as set at 2; P4D15 and
P4J5 values were above this threshold.
Multiple categories of chemically related structural groups were identified.
Comparison to known AHR ligands revealed many structures with potential ligand
activity. From these structures, we performed dose responses of the structures we thought
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had a relationship with well-known AHR ligands. The first drug we compared with a
well-known AHR ligand was P1E4 (Figure 4) the doses we chose for this compound dose
response were 0.003, 0.01, .03, .1, .3, 1, 3, 10, and 33 M. P1E4 was shown to have a
significant AHR activation at 0.1 M and increased its response all the way until 33 M
with no significance cell toxicity shown. (Figure 5)

Figure 4. A pharmacophore comparison of PAH a well stablished AHR activator and P1E4.

Figure 5. P1E4 dose response in Caco2 cells. The maximum effective dose found at 33
M with no significance effect in toxicity.
Another drug we decided to pursue was the drug in the well P4D15 (Figure 6),
this drug had similarities with the well-known AHR activator FICZ. For the drug
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response of this drug we used the doses 0.01, .1, 1 and 10 M where we started to see a
significant response at 10 M with no significance toxicity (Figure 7).

Figure. 6 is a pharmacophore comparison of FICZ a well stablished AHR activator and
P1E4.
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Figure 7. P4D15 dose response in Caco2 cells. The maximum effective dose was found at
33 M with no significance effect in toxicity.
Cells were seeded in a 96 well plate at a density of 12.5x104 cells per well and
allowed to incubate at 37C for 24 hours before transfection. For the method for
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transfection, HepG2 cells were transfected using FuGene6. The method for transfection
and treatment was as follows: In a sterile polypropylene tube, 500 L of serum-free
medium were added followed by 15 L of FuGENE 6. After the addition of FuGENE 6
the pTBXMG plasmid was added followed by the tomato plasmid. After the addition of
both plasmids the tube was tapped gently to mix and was then incubated for at least 15
minutes. After incubation the medium-free serum with the plasmids was transferred to each
well of the 96-well plate (5L per well). After successful delivery of the plasmid, the cells
were incubated for 24 hours before treatment. The analysis was carried out 24 hours after
the treatment of the quinone of interest.
Quinone Structure Analysis
For benzoquinone dose response the doses used were 3.75, 7.5, 15, 30, and 60 M
(Figure 8.). This structure was chosen as it provided a quinone structure with the least
amount of substituted carbons in the para-quinone structure in order to test the hypothesis
in question.
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Figure 8. Benzoquinone showed to be an activator of the AHR with no significant toxicity.
In contrast with this we choose a quinone that lacked double bounds in its structure
making it not a quinone but similar to the para-quinone structure. The chemical used was
1,4 cyclohexadione (Figure 9) with comparable doses to benzoquinone.

Figure 9. Even at high doses, 1,4 Cyclohexadione showed no AHR activity.
For the methylbenzoquinone dose response the doses used were 0.5, 1, 5, 10, 25, 50, 60,
and 70M (Figure 10).
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Figure 10. Methylbenzoquionone showed higher potency when compared with tBQ with
the highest response at 60M and showing a decrease to response probably due to
toxicity at 70 M.
For the tBQ dose response, the doses chosen were 0.03, 1, 3, 10, 33, 50 L
(Figure 11).

Figure 11. tBQ was agonist of the AHR, showing highest response at 33 L, followed by
cell toxicity at 50 L.
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As shown in the following graph for 2,6-dimethyl benzoquinone dose-response
we used the same doses that we used for methylbenzoquinone (Figure 12).

Figure 12. 2,6-dimethylbenzoquinone showed to be less potent when compared to tBQ
and methylbenzoquinone. With the highest response at 60 M and decrease in response
probably due to cell toxicity at 80 M.
For 2,5 Dimethyl benzoquinone dose response the same doses that were used for
methylbenzoquinone were used (Figure 13).

Figure 13. 2,5 dimethylbenzoquinone showed to be less potent when compared to tBQ
and methylbenzoquinone as well but in contrast to 2,6 dimethyl benzoquinone, 2,5
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dimithylbenzoquinone was more potent and less toxic. With the highest response at 60
uM and decrease in response probably due to cell toxicity at 80uM.
For the trimethylquinone (TMQ) a dose-response of 1, 3, 6, 12, 25 and 50M
more chosen (Figure 14). In contrast with the previous paraquinones, TMQ did not
showed a significant activation when compared to control, nor it show a change between
doses.

Figure 14. Trimethylquinone (TMQ) did not show a significant activation when
compared to control, nor it show a change between doses.

For the duroquinone the same doses and dose increments as tBQ dose-response
were chosen (Figure 15).
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Figure 15. Duroquinone, similarly to TMQ showed no significance activation when
compared to control. Nor it showed any change between doses.
Tert-butyl hydroquinone (TBHQ) (Figure 16), the reduced form of tBQ; and HQ
(Figure 17), the reduced form of BQ were also analyzed.

Figure 16. Reducing tBQ to TBHQ seemed to have abrogated the activity of the
paraquinone to activate the AHR.
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Figure 17. Contrary to the findings seen in the reduced form of tBQ, reducing BQ to HQ
showed an increase in AHR activity.
After finding different para-quinones with AHR activity it was necessary to
further validate that the emission of green fluorescent light was dependent to AHR
activation and not activation of the MMTV portion by itself nor activation by the
glucocorticoid response element. Therefore an experiment was carried out transfecting
the cells only with MMTV, lacking the dioxin response element portion. In the
experiment, the cells were treated with the different ligands we found at 25 M (Figure
18). Additionally we used dexamethasone as our positive control as the MMTV plasmid
would be activated if there was binding in the glucocorticoid response element.
Dexamethasone, a glucocorticoid, is an established activator of MMTV promoter activity
in cells expressing a glucocorticoid receptor. In this study, dexamethasone was found to
effectively stimulate the MMTV promoter in pMMTVdsEGFP (Figure 18). However,
none of the quinone structures investigated were found to activate the MMTV promoter
that did not contain a DRE suggesting that quinone activation of GFP expression from
pTBXMG was dependent on the presence of a DRE (Figure 18).
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Figure 18. Treatment of cells transfected with plasmid lacking the dioxin response element
with para-quinones did not emit green fluorescent light compared to the cells treated with
dexamethasone.
Cytotoxicity was determined for each quinone using the CyQuant assay. Select
quinone analysis of toxicity produced by DQ, BQ, MQ, and 2, 6 dimethylquinone is shown
in Figure 19.
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Figure 19. Quinone toxicity assessed 24 h after treatment for duroquinone, benzoquinone,
methylquinone, and 2,6 dimethyl quinone at 25, 50, and 100 M.
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AHRA assay activation for each quinone at 25 M was also assessed illustrating
significant differences in the potency of each quinone (Figure 20).
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Figure 20. Quinone activation of the AHR was assessed using the AHRA assay 24 h after
treatment.
Table 1 shows collective quinone data for EC50, AHRA assay results at 25 M, as
well as 24 h viability data at 25 and 50 M for HepG2 cells.
Table 1. Potency and toxicity data for the para-quinones investigated in HepG2 cells
Quinone

EC50
(M)

AHRA
Assay at
25M

Viability
25M
(% control)

Benzoquinone (BQ)
7.5
115
1,4 Cyclohexanedione (CHD)
NA1
26
tert-Butylquinone (tBQ)
10
239
1
tert-Butylhydroquinone (tBHQ)
NA
32
Methylbenzoquinone (MQ)
10
187.5
2,5-Dimethylbenzoquinone (2,5DmQ)
18
51
2,6-Dimethylbenzoquinone (2,5DmQ)
20
52
1
2,3,5-Trimethylbenzoquinone
NA
10
(2,3,5TmQ)
Duroquinone (DQ)
NA1
7.5
2
Tocopherylquinone (TQ)
ND
ND2
1
No AHR activity up to the highest concentration investigated.
2
Not determined.
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Viability
50M
(% control)

88
93
88
111
85
92
90
95

74
104
77
99
66
89
61
85

98
103

99
101

Discussion
In this study, a highly flexible cell-based high-throughput assay for screening
drugs that modulate AHR activity was successfully developed and designated the AHRA
assay. There was a difference observed in the assay sensitivity between Caco2 cells and
HEPG2 cells that could be accounted to different levels of AHR expression between the
cell lines or due to the different transfection methods. Further studies would be necessary
in order to elucidate which factor made the difference in sensitivity between the assay.
From the Prestwick Chemical Library, 8 distinct compounds were recognized as
relatively potent AHR activators, which have not previously been recognized as altering
AHR activity. In addition, the oxidation product of vitamin E, tocopherylquinone (TQ),
was found to activate the AHR. As TQ has been investigated as a treatment for diseases
such as Friedrich’s Ataxia (Lynch et al., 2012), TQ was pursued as a “lead compound”
for further drug repurposing. The quinone component of TQ was found to be an essential
functional group for TQ’s ability to activate the AHR. Therefore, quinones similar to the
structure found in TQ were investigated as chemical structural variants to identify those
with the greatest potential for activating the AHR. Interestingly, substitution of both the
type and number of groups on the para-quinone structure was found to have a significant
impact on the ability of quinones to activate the AHR. The information acquired in this
research should prove useful in novel drug design for safe and effective agents to
modulate AHR activity therapeutically.
The dose response analysis of different quinone structures with different number of
carbon substitutions showed a direct relationship with the number of positive cells after
treatment. When comparing the potencies of the quinone structures to activate the AHR
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there is a significant decrease as the number of substituted carbons reaches 2 and higher.
Another thing that is important to note is that the structure of the quinone is not the only
thing necessary to activate the AHR as the experiment comparing benzoquinone with 1,4
cyclohexanedione showed that the ability of the structure without double bounds
completely lost its potency to activate the AHR regardless of structure. From these studies
we believe that some of these quinones such as TQ have the potential to be used as a novel
treatment of inflammatory bowel disease as this structure showed a significant potency to
activate the AHR without causing significant toxicity to the HepG2 Cells.
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CHAPTER 3: CONCLUSIONS AND FUTURE STUDIES
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Conclusion
From the results provided by the dose responses of different quinone structures with
variation on carbon substitution it can be concluded that quinone activation of the AHR is
dependent on the number of substituted carbons in the para-quinone structure. As seen by
our experiments, one of the structures with most activity for the AHR was BQ and as the
number of substitutions on the structure increases by either methylation or reduction; so
did their activity for activating the AHR. However, we also observed that adding a methyl
group to the BQ increased its potency for AHR activation, eluding to the fact that AHR
activation by para-quinone structures is not only dependent on the number of substitutions
on the para-quinone structure, but the size and the characteristics of the groups on each
carbon, as well.
Future Directions
The data presented on this thesis begins to address pharmacophore relationships of
para-quinones and AHR activation. I have presented that para-quinones have the ability to
activate the AHR given that they fulfil a certain number available unsubstituted carbons in
their structure. In addition, I have shown that there is a relationship between the number
substitutions in para-quinones and their toxicity. This section will focus on addressing
additional questions that arose from these studies and validation studies necessary for
further pharmacologic considerations of the AHR.
Validation Studies
The hypothesis driving the study was; Established drugs serve as model
compounds to evaluate the aryl hydrocarbon receptor as a pharmacologic target. To begin
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addressing the hypothesis, quinones were identified as lead compounds, through an AHREGFP reporter assay. One of the first studies that should be performed in order to validate
our assay is the use of HepG2 cells with AHR knockout transfected with the pTBXMG
plasmid. If the number of positive cells becomes nonexistent it would provide further
evidence that our assay is dependent on AHR activation. Another thing to consider is that
the pathway of AHR activation is complex and activation of the AHR can be independent
of para-quinone binding to the AHR. For example, CYP1A1 is responsible for
metabolizing both xenobiotic and endogenous ligands of the AHR. Hence, inhibition of
CYP1A1 may cause an accumulation of other natural compounds in the cells which may
result in an indirect activation of the AHR. Thus, I propose two different studies to discard
AHR activation through CYP1A1 blockade as the pathway responsible for AHR activation
by para-quinones. The first study proposed is the measurement of ethoxyresorufin-Odeethylase (EROD) activity. CYP1A1 mediates the deehylation of 7-ethoxyresorufin (7ER) to form resorufin (Whyte and Jung 2008). Consequently, the concentration of resorufin
produced per mg/protein/minute is indicative of CYP1A1 activity (Kennedy and Jones
1994). If the para-quinones activate the AHR through CYP1A1 blockage, it would be
expected for the EROD assay to report a low concentration of resorufin in addition of
reported AHR activation. The second study that can shed light to this question is evaluating
whether or not para-quinones are substrates of CYP1A1 and the rate by which CYP1A1 is
able to metabolize para-quinones into inactive-compounds. As mentioned before, CYP1A1
is responsible for metabolizing activators of the AHR. As a result, the activation of the
AHR could be skewed due to a low rate of metabolism and an increase time of exposure
of the AHR to the para-quinone. An additional study to validate AHR activation is the
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measurement of CYP1A1 up regulation through a western blot analysis. Both of these
studies in addition to our EGFP reporter assay would help provide stronger evidence of
AHR activation by our lead compounds.
In addition to the CYP1A1 validation studies it would be important to have a better
understanding of the relationship of para-quinone AHR activation and CYP1A1. The
proposed mechanism to investigate this question in a greater detail is the use of cells with
CYP1A1 knockout. There are multiple outcomes that could occur with this experiment
including but not limited to; an increase in AHR activation or no change in the amount of
AHR activation. From all these different possible outcomes critical information could be
drawn to further understand the involvement of CYP1A1 and para-quinone AHR
activation. For instance, an increase in the activation of AHR in CYP1A1 knockout cells
could mean that the para-quinone is a ligand for CYP1A1 and that CYP1A1 may be
necessary for the metabolism of the ligand, which may be an interesting finding as it could
also change the toxicity seen by the para-quinone. On the other hand, no change in AHR
activation may support the idea that AHR activation by para-quinones is independent of
CYP1A1.
Future Studies
In this thesis I have shown novel ligands with the ability to activate the AHR but
the question about their use in pharmacotherapy is still elusive. This section will be focused
on my suggestions of the studies that would need to be done before using this compounds
in pharmacotherapy.
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Understanding Aryl Hydrocarbon Receptor’s Role in Biology
It has already been stablished that the AHR plays a role in immunology, including
inflammation (Stockinger et al., 2014). But there is still a discrepancy on the actual
function of the AHR and the contribution that it has in immunology which I believe is
attributed to the fact that the AHR has multiple ligands. Therefore, the outcome of
activating the AHR has to be an independent consideration for each ligand. Due to this
concept I propose that cell studies be performed with our proposed ligands TQ, BQ, and
MQ to figure out which ligand results in the modulation of inflammatory responses
through AHR activation. Screening for proteins and cytokines involved in inflammation
is a possibility to assess the ligands involvement in inflammation. Among the different
cytokines and proteins, interleukin-22 (IL-22) stands out as a possible biomarker for
AHR mediated inflammation. Kiyomatsu-Oda recently published a study that looked at
the potential of FICZ to treat chronic eczema. In the study Kiyomatsu-Oda stimulated
HaCaT cells and normal human epidermal keratinocytes (NHEKs) with or without FICZ
and then performed quantitative reverse transcriptase polymerase chain reaction,
immunofluorescence, and siRNA treatment. In the study Kiyomatsu-Oda utilized atopic
dermatitis-like NC/Nga murine model and treated the mice for 2 weeks with either
Vaseline as a control, FICZ ointment, or betamethasone 17-valerate ointment
(Kiyomatsu-Oda et al., 2018) The results from the study showed that FICZ reduced
atopic dermatitis-like skin inflammation and expression of IL-22 through AHR activation
in mice (Kiyomatsu-Oda et al., 2018)
In addition to the immunology cell studies there also needs to be animal
experiments that look deeper into the AHR function. For these experiments, genetically
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engineering mice with double knock out of the AHR in different parts of the body could
be very useful. It would be important to know the difference in tissue and embryonic
development these mice undergo after removing the expression of the AHR. The reason
why it would be important to perform the experiments in different tissue is to further
understand if AHR function is dependent on its location.
Inflammatory Bowel Disease Applications
Currently the capabilities of TQ to reduce inflammation in mice after TNBS
induced colitis is being tested with promising results. These unpublished results support
the concept of using TQ as a possible alternative therapy for the treatment of
inflammatory bowel disease. Nonetheless, toxicity studies have to be performed in mice
in order to be able to determine what the minimum effective dose (MED) is and the
minimum toxic dose in order to extrapolate the therapeutic index for TQ. Extrapolating
the therapeutic index of TQ will help give a starting dose for starting experimental studies
in humans. After efficacy and safety are established in humans a number of studies would
need to be performed in order to establish if TQ has a place in therapy. These, studies
would have to be non-inferiority studies comparing TQ with the current standard of care
for inflammatory bowel disease.
Other Applications
Current treatments for immune mediated diseases have different limitations which
I believe could be overcame by the use of the AHR as a pharmacological target Among
the complications of treating immune mediated diseases is the fact that many of these
therapies are not specific and have systemic and long-lasting effects. For instance,
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steroids which are a commonly used for the treatment of immune mediated diseases have
effects such as tissue atrophy or adrenal suppression which can be seen even after
stopping the drug. These side effects can be very significant and can limit the use of
steroids to certain populations. Currently, monoclonal antibodies are a class of drugs that
are more selective which can circumvent many of the problems that are faced by steroids.
However, these therapies are still extremely expensive which makes it difficult to be used
in therapy. Hence, AHR ligands present an opportunity to broaden our pool of agents
used to treat immune mediated diseases as the proposed repurposed drugs in this studies
are very cheap in comparison to the monoclonal antibodies and there is extensive data in
each molecule. In this thesis it is proposed that there are many ligands that are already in
the market that show low toxicity that could be repurposed for their use in immune
mediated diseases. Also, according to the studies reviewed, the effects of the AHR are
not long lasting after ligand exposure in contrast with steroids. The experiments that I
suggest is the use of TQ as an adjunct therapy to the standard of care. Studies should be
performed where there is a patient group with an immune mediated disease under
standard of care plus placebo and comparing it to another group of patients taking TQ.
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Abstract
The pharmacological modulation of autophagic processes is under investigation for
treating a diverse group of human diseases including for cancer chemotherapy.
Autophagy is a homeostatic cellular pathway involved in the turnover of organelles,
aggregated proteins, cell remodeling, and regeneration of nutrients, such as amino acids,
for cell survival during stress. We have identified astemizole (AST) as an agent that
inhibits growth, induces cell death, and modulates autophagy in prostate cancer cell lines.
AST was found to visibly increase intracellular granularity in a dose-dependent manner
in all human prostate cancer cell lines tested, including the androgen-sensitive 22Rv1and
LNCaP lines as well as in androgen-independent PC3 cells. Increased levels of
intracellular granularity were quantified by side-scatter using flow cytometry.
Additionally, AST produced a dose-dependent decrease in cell growth and viability in all
prostate cancer cell lines tested, where 22Rv1 cells were most sensitive and LNCaP cells
were found to be most resistant. Higher doses of AST led to an abrupt cell death in
prostate cancer cell lines. AST also increased punctae formation of EGFP-LC3 II and
acridine orange staining of intracellular granules, strongly supporting alterations in
autophagic pathways by AST. Docetaxel or radiation, an established modulator of
autophagy, enhanced AST-induced cell killing. Cellular fragmentation was enhanced by
the combination of radiation and AST. AST significantly increased LC3 II levels,
showing AST to be a dose-dependent modulator of autophagic flux in prostate cancer
cells. The combination of radiation and AST acted synergistically to increase LC3 II
levels as a further indicator of cellular autophagy modulation. Together, results from
these studies suggest that chemical modulators of autophagy such as AST shift the
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balance of autophagic processes toward prostate cancer cell death that may prove to be a
useful strategy for cancer treatment.

Introduction
Prostate cancer is the most frequently diagnosed form of cancer among men in the
United States and a leading cause of cancer deaths (Jemal et al. 2017). Strategies for
prostate cancer treatment are limited and, at present, rely principally on targeting
androgenic activity, which promotes prostate cancer progression in early, advanced
disease (Helsen et al. 2014). Despite an initial efficacy for this approach, prostate cancer
invariably advances to a state refractory to antiandrogenic therapy. Targeting prostate
cancer through mechanisms other than androgenic pathways relies on a thorough
understanding of metabolic pathways essential to prostate cancer progression. Thus,
targeting metabolic pathways important to prostate cancer progression may enable the
development of novel therapies for this disease.
Autophagy, a cellular homeostatic system for recycling of metabolic substances,
has been proposed as a target for cancer therapy. The process of autophagy can degrade
aggregate proteins, protein complexes, and whole organelles (Van Limbergen et al.
2009). Under conditions of nutrient deprivation, this process may be activated to provide
amino acids and fatty acids to sustain the basic energy needs of the cell (Kung et al.
2011). In this manner, the autophagic process allows both for efficient recycling of
cellular components and for establishing a cellular metabolic balance between energy
consumption and production (Levine and Klionsky 2004). Macroautophagy is an
extensively investigated form of autophagy that is characterized by the formation and
59

accumulation of double membrane intermediate vesicles (Loos and Englebrecht 2009).
Macroautophagy is the process most commonly referenced simply as autophagy, which is
the term used here.
To date, considerations to target autophagy for cancer therapy have proven
controversial. This is in part due to an incomplete understanding of the dichotomy of
autophagy’s role in cell survival and cell death (Wu et al. 2012; Zhou et al. 2012).
Gewirtz (2014) suggests that autophagic processes in cancer therapy have up to four
functions. These include a cell protective function that, when inhibited, sensitizes cancer
to therapies and a cytotoxic function that promotes cancer cell killing. Other proposed
autophagic functions either do not affect cancer therapies or have a role in cytostasis
where inhibition may produce resistance to cancer therapies (Gewirtz, 2014). Studies
have shown that either insufficient or excessive levels of autophagy can signal cell death
pathways, whereas intermediate levels can facilitate cell survival (Kang et al 2007). In
prostate cancer therapy, preclinical data provides evidence that autophagy may be
involved in therapeutic resistance and disease progression; yet inhibition of autophagy
can enhance cell killing produced by cancer therapies (Farrow et al. 2014). The
development of novel methods to modulate autophagy therapeutically would help resolve
the ambiguity of autophagy in cancer therapy.
The Prestwick Chemical Library was screened using a high-throughput HyperCyt
flow cytometry system to identify inducers of autophagy in prostate cancer cells (Haynes
et al. 2009). The initial basis for the screening used side-scatter as an endpoint. The
production of vacuolar structures, which may include autophagosome and autolysosome
structures that lead to increased intracellular granularity. The agents present in the
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Prestwick Chemical Library were selected for their high chemical and pharmacological
diversity as well as for their known bioavailability and safety in humans and may prove
useful for repurposing their therapeutic use (Oprea et al. 2011). The initial screening
encompassed a diverse range of pharmacological activities, including the antihistamine,
astemizole. In this study, astemizole was investigated for its potential to modulate
autophagic and cell death pathways in prostate cancer cells.

Materials and Methods
Chemicals
Astemizole (AST), IGEPAL CA-630, pentamethylsulfonyl fluoride, sodium
dodecyl sulfate, aprotinin, sodium deoxycholate, and sodium orthovanadate were
obtained from Sigma Aldrich (St. Louis, MO). Docetaxel was obtained from LC
Laboratories (Woburn, MA).
Cell culture and cell culture reagents
The 22Rv1, LNCaP, and PC3 human prostate cancer cell lines were obtained
from ATCC (Manassas, VA). Prostate cancer cell lines were maintained in Dulbecco’s
modified Eagle’s medium (DMEM; Invitrogen, Carlsbad, CA) containing 5% heatinactivated fetal calf serum (FCS; Sigma, St. Louis, MO) with streptomycin-penicillin
antibiotics (designated F5A1) in a 5% CO2 incubator at 37C.
Cell viability and cell proliferation assays
Relative cell viability changes were determined using cells plated in 12-well
tissue culture plates (Costar, Corning, NY) in F5A1 media at 3104 cells per well. AST
was administered at the specified concentrations with 1,000 stock solutions dissolved in
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ethanol. Cell viability was determined using trypan blue dye (0.4%; Sigma, St. Louis,
MO) exclusion and cell counts determined using a hemocytometer and light microscopy.
Prostate cancer cell growth analyses were performed using LNCaP and PC3 cells plated
in 96-well tissue culture plates (Costar, Corning, NY) initially plated at 1,000 cells per
well in F5A1. Relative cell numbers with and without AST treatment were determined
using the CyQUANT NF Cell Proliferation Assay Kit (Invitrogen), according to kit
instructions.

Cellular granularity and fragmentation determinations using flow cytometry
For cellular granularity and fragmentation analysis, PC3 cells were plated in 12well tissue culture plates (Costar, Corning, NY) at 3104 cells per well. AST was
administered at the specified concentrations using 1,000 stock solutions dissolved in
ethanol. A BD FACScan System flow cytometer (BD Biosciences, San Jose, CA) was
used for forward- and side-scatter measurements. FlowJo software (FLOWJO, LLC,
Ashland, OR) was used for analysis of flow cytometric data. To determine levels of
cellular fragmentation induced by radiation and AST, a BD Accuri™ C6 flow cytometer
(BD Biosciences) was used with data analysis performed using Accuri™ C6 Software
(BD Biosciences).
Radiation Exposures
For radiation exposures, PC3 or 22Rv1 cells were plated in 6-well tissue culture
plates (Costar, Corning, NY) at 4104 cells per well. AST was administered at the
specified concentrations using 1,000 stock solutions dissolved in ethanol for the
specified time periods. Cellular radiation exposures were performed using a Gammacell
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40 (137Cs) Irradiator (Atomic Energy of Canada, Ltd., Ottawa, ON, Canada), according to
instrument instructions, available through the UNM Health Sciences Center at the
radiation doses specified.
Immunoblotting
LC3 lipidation analysis as an increase in LC3 II was determined for AST. Cells
were plated at a density of 106 cells per 100 mm cell culture plate in 10 ml of
DMEM/CSS and maintained in incubators at 37°C in 5% CO2. After treatment with
vehicle or AST, cells were washed in cold 1 PBS and lysed in a buffer containing 1.0 %
IGEPAL CA-630, 0.5 % sodium deoxycholate, 0.1 % sodium dodecyl sulfate, 0.1 mg/ml
phenylmethylsulfonyl fluoride, 1 mM sodium orthovanadate, and 10 µg/ml aprotinin in
1 PBS. Cell extracts were stored at -80°C until analysis. Sample protein levels were
determined using the BCA Protein Assay kit (Pierce Biotechnology, Rockford, IL)
according to kit instructions. Total protein (25 to 30 µg) from cell extracts were
electrophoresed on 10-20% Criterion Precast gels (BioRad, Hercules, CA) and
transferred to Immobilon-P membranes (Millipore Corp., Bedford, MA) using a GENIE
wet transfer system (Idea Scientific, Minneapolis, MN). Membranes were blocked in
Tris-buffered saline containing 5% nonfat dry milk at 4°C and incubated with anti-LC3
polyclonal antibody (PM036; MBL International, Woburn, MA) or mouse anti-β-actin
antibody (A5441; Sigma). After washing, membranes were incubated with a secondary
horseradish peroxidase-conjugated goat anti-rabbit (SouthernBiotech, Birmingham, AL)
or anti-mouse IgG (Biomeda, Foster City, CA) and analyzed using Western Lightning
Chemiluminescence Reagent Plus (PerkinElmer, Waltham, MA) on a ProteinSimple
FluorChem R instrument (ProteinSimple, San Jose, CA) according to instrument
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instructions. Band intensities were determined using Protein Simple Molecular Imaging
Software.
PC3.EGFP-LC3 cell and acridine orange staining analysis
PC3.EGFP-LC3 cells, PC3 stably transfected with pEGFP-LC3, were generated
as previously described using PC3 cells instead of LNCaP cells (Kaini, et al. 2012).
PC3.EGFP-LC3 cells were treated with 10 µM AST for 24 hours and then examined by
fluorescent microscopy. To analyze acidic vesicles associated with autophagy, PC3 cells
were treated for 24 hours with 10 M AST, wash with 1 PBS and then stained with the
lysosomotropic agent acridine orange (ThermoFisher Scientific, Eugene, OR).
Photomicrographs were obtained as specified under “Light and fluorescent microscopy”.
Both PC3.EGFP-LC3 cell and acridine orange stained PC3 cells were analyzed using an
excitation filter at 490.
Light and fluorescent microscopy
Both light and fluorescent photomicrographs were captured using an Olympus
IX70 Inverted Fluorescent Microscope equipped with an Olympus DP72 camera.
Olympus cellSens Dimension 1.13 Life Science Imaging Software (Olympus, Waltham,
MA) was used for image capture.
Statistical Analysis
Significant differences in values between groups were assessed using an unpaired
t-test with SigmaStat 3.1 software (Systat Software, Inc., San Jose, CA). P values less
than 0.05 were used to signify statistical significance. Determination of tumor growth rate
was performed using standard procedures for simple linear regression analyses.
Determination of synergism between treatments were made as recommended for
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GraphPad Prism (GraphPad Software, Inc.,La Jolla, CA). Studies were performed as
specified with a minimum of 3 samples per group (i.e., n ≥3).

Results
The effects of AST on prostate cancer cell viability and proliferation in cell
culture were determined. Trypan blue exclusion and hemocytometry was used to examine
the dose-response of androgen-sensitive 22Rv1 and LNCaP cells and androgenindependent PC3 human prostate cancer cells after 48 h AST treatment (Fig. 1A). The
androgen-sensitivity of the different prostate cancer cell lines did not determine
sensitivity to AST-induced cell death as the androgen-sensitive 22Rv1 and LNCaP cells
were found to be more sensitive and resistant to AST, respectively, than PC3 cells (Fig.
1A). The 22Rv1 cells were found to be most sensitive with significant cell death
observed at 5 M AST, whereas LNCaP and PC3 cells were not significantly affected at
this dose of AST (Fig. 1A). PC3 cells were found to be affected by 10 M AST and
LNCaP cells were the most resistant to AST-induced cell death (Fig. 1A). Further
analysis of AST effects on prostate cancer cell proliferation at non-lethal doses of AST
(i.e., 0.5 to 5 µM AST) was determined over 96 h. PC3 cells showed a significant
decrease in cell growth when treated with doses of 2.5 and 5 M AST, but were
unaffected by doses of 0.5 and 1.0 M AST (Fig. 1B). LNCaP cells showed a decrease
in cell proliferation at 5 M AST, whereas the growth of these cells was not affected by
doses of 0.5 to 2.5 M AST (Fig. 1C). Significant cell death was observed in both PC3
and LNCaP cells treated with 10 M AST for 96 h (Figs. 1B and 1C). Thus, the
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sensitivity to AST on prostate cancer cell death and proliferation was dose and cell type
specific.
We and others have reported the production of observable intracellular granularity
in cells following treatment with a variety of drugs, including AST (Haynes et al. 2009;
Jakhar et al. 2016). Fig. 2A, B, and C show the microscopic presentation of intracellular
granularity in PC3 cells following treatment with 10 M AST compared to control,
untreated cells. We have developed methods to quantify intracellular granularity by
analyzing side-scatter (SSC) using flow cytometry (Haynes et al., 2009). For example,
Fig. 2D and 2E shows the increase in SSC observed in PC3 cells following 48 h
treatment with AST observed as SSC using flow cytometry. This method allows the
quantification of increases in granularity induced by AST treatment. Fig. 2F shows the
dose-response of AST-induced increases in SSC (i.e., granularity) after treatment of PC3
cells. PC3 cells showed 77% intracellular granularity after treatment with 3 M AST
compared to 10% in untreated cells (Fig. 2F). Interestingly, cells with significant death,
which was observed at 10 and 30 M AST, had lower levels of intracellular granularity
compared to the peak levels observed with 3 M AST (Fig. 2F).
To determine if the induction of intracellular granularity was coincident with the
induction of autophagy, biomarkers of autophagy were assessed after AST treatment in
prostate cancer cells. An initial indication of autophagic induction in prostate cancer
cells was provided by the observation of the production of punctae in PC3 prostate cancer
cells stably expressing EGFP linked to the LC3 protein, a useful marker of autophagy
(Fig. 3A – control, untreated; Fig. 3B – AST treated). An additional assay for autophagy
was performed showing acridine orange staining of acidic autophagic vacuoles (Paglin et
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al. 2001) in PC3 cells, producing a bright orange-red fluorescence (Fig. 3C – control,
untreated; Fig. 3D – AST treated). An early event in autophagosome production is the
lipidation of LC3 (i.e., ATG8; Klionsky et al. 2016). Formation of lipidated LC3 (LC3 II)
is readily observed by immunoblotting. Fig. 3E demonstrates the induction of increased
LC3 II expression following treatment of 22Rv1 prostate cancer cells with AST. Taken
together, these studies provide strong evidence that AST can modulate autophagy in
prostate cancer cells.
Radiation is used extensively in the treatment of prostate cancer (Pugh et al.
2013). Studies were performed to determine the effects of radiation combined with AST
treatment on prostate cancer cell killing. Exposure to 5 and 10 Gy radiation resulted in
decreased PC3 cell viability after 24 h (Fig. 4A). Doses of AST higher than 7 µM
significantly augmented radiation induced cell killing (Fig. 4A). The effects of combined
radiation and AST were also examined for induction of autophagy. The combination of 5
Gy and 8 µM AST, administered 1 h before radiation, synergistically increased levels of
LC3 II protein after 24 h radiation exposure suggesting that the combination of radiation
and AST significantly modulated autophagy in PC3 cells (Fig. 4B). Doses of AST and
radiation that killed PC3 cells were found to significantly reduce cell numbers, below the
cell numbers originally plated. To determine if these interventions induce PC3 cell
bursting, cellular fragmentation was measured by scatter patterns using flow cytometry.
Both 5 and 10 Gy radiation, 10 and 15 µM AST, and the combination of each were found
to increase cellular fragmentation (Fig. 4C, 4D, 4E, and 4F). Indeed, a close correlation
between levels of cellular fragmentation and cell death induced by AST and radiation
was observed. In addition to PC3 cells, the combination of radiation and AST was found
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to enhance cell killing in 22Rv1 prostate cancer cells (Table 1). For example, the
combination of 10 Gy radiation with 2, 4, or 8 µM AST increased cell killing, where the
combination of 10 Gy radiation and 4 or 8 µM AST acted synergistically to enhance cell
killing (Table 1). In addition, the combination of 10 nM docetaxel, used in the treatment
of advanced, hormone-refractory prostate cancer, with 2, 4, or 8 µM AST increased
22Rv1 cell killing (Table 1). Thus, radiation and chemotherapeutic prostate cancer cell
killing was augmented by the co-administration of AST.

Discussion
The drug AST, a second-generation H1-receptor antagonist, has been considered
for repurposing from its use as an antihistamine to other applications, including cancer
chemotherapy (Garcia-Quiroz and Camacho, 2011). In this study, AST was shown to
modulate autophagic and cell death pathways in human prostate cancer cells. Variability
in the sensitivity to AST-induced cell death was observed among the prostate cancer cell
lines examined, which included the androgen-sensitive 22Rv1 and LNCaP cells as well
as the androgen-independent PC3 prostate cancer cell line. Due to the variation in AST
response observed among androgen-sensitive prostate cancer cell lines, it is unlikely that
the sensitivity of prostate cancer cell lines to AST-induced cell death is dependent on
androgen responsiveness. Further, both increases in intracellular granularity and the
modulation of autophagic pathways by AST were observed in all prostate cancer cell
lines examined, independent of androgenic sensitivity of the cell line treated.
Although AST has not been investigated extensively as a potential therapeutic
strategy in prostate cancer, it has demonstrated potential in other cancer cell types. For
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example, de Guadalupe Chavez-Lopez et al. (2014) have shown efficacy of AST against
multiple cervical cancer cell lines. Further, García-Quiroz et al. (2014) have shown in
vivo effectiveness utilizing a combination of calcitriol and AST against breast cancer.
AST is known to inhibit the Ether-á go-go-1 (Eag1) potassium channel (Garcia-Ferreiro
et al. 2004). For example, Diaz et al. (2009) showed that Eag1 expression in numerous
cancer cell types and reported that AST exposure could increase apoptosis in
keratinocytes. These authors concluded that Eag1 was an early indicator of cell
proliferation leading to malignancies and could be a therapeutic target for
hyperproliferating cells.
The data presented herein suggests that AST has potential for in vivo activity and
that it might be useful for augmenting current approaches to enhance therapeutic efficacy.
Indeed, combination therapy has been suggested as a way that inducers of autophagic cell
death may complement existing cancer therapies. For example, recently Peng et al (2008)
reported that berberine, an isoquinoline alkaloid and inducer of autophagy in lung cancer
cell lines, potentiates the anti-cancer effects of radiation. Moreover, these investigators
showed this combination therapy to be effective in preclinical animal models. In the
current study, the in vivo efficacy of AST against prostate cancer growth was determined
using a xenograft transplantation model in nude mice. A significant growth inhibition of
PC3 tumor cells in mice given daily oral doses of AST for 3 weeks was observed. This
data, in combination with observations illustrated in Fig. 5, provide promise that AST has
in vivo activity that might be useful for augmenting current therapeutic approaches to
enhance therapeutic efficacy. Indeed, combination therapy has been suggested as a way
that inhibitors of autophagy may complement existing cancer therapies (Livesey et al.
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2009; Farrow et al. 2014). As noted previously, we have observed that AST potentiates
cell killing in 22Rv1 prostate cancer cells exposed to 10 Gy radiation in combination with
4 µM and 8 µM AST (Table 1). These data demonstrate that modulation of autophagy
can increase the efficiency of prostate cancer cell killing with established prostate cancer
therapies.
New developments in the understanding of autophagy have led to the realization
that cell death via autophagy represents a mechanism of cell death distinct from apoptosis
which has been termed programmed cell death type II (Kondo & Kondo, 2006). The
selective induction of cell death is a characteristic exploited for cancer
chemotherapeutics. The process of autophagy clearly plays an important role in
regulation of cancer development and progression and has been implicated as a factor
contributing to the sensitivity of tumor cells to anticancer therapy (Kondo et al 2005;
Bursch et al 1996; Shingu et al 2009). The identification of compounds that selectively
kill cancer cells through induction of autophagy would significantly expand the
therapeutic options for cancer treatments. Studies are currently underway to examine the
interplay between AST-induced autophagy modulation and prostate cancer cell death.
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Figure Legends
Fig. 1. AST-induced changes in human prostate cancer cell line growth and viability. (A)
Differences in AST dose-response for cell viability were determined for androgensensitive 22Rv1 and LNCaP human prostate cancer cell lines; and in the androgenindependent PC3 prostate cancer cell line, 48 h after AST treatment. AST induced a dosedependent decrease in cell growth in the PC3 cell line (B) as well as the LNCaP cell line
(C) 96 h after AST treatment. *P<0.05 compared to control; # indicates significant cell
death compared to control cells.

Fig. 2. Granularity analysis of PC3 human prostate cancer cells treated with AST. (A)
Vehicle-treated control cells, low power; (B) cells treated with 10 M AST; (C) higher
power with 10 M AST. Flow cytometric analysis of forward- (FSC-H) and side-scatter
(SSC-H) changes in untreated (D) or 10 µM AST –treated PC3 prostate cancer cells (E).
The R1 gate (i.e., red gate) was set to determine AST-induced changes in SSC as a
measure of cellular granularity. (F) AST dose-response analysis of granularity as
measured by changes in SSC. AST doses of 10 M or greater produced significant PC3
cell death with lower levels of SSC compared to cells treated with 3 M AST.

Fig. 3. Modulation of autophagy by AST in human prostate cancer cells. Control,
vehicle-treated PC3 cells show low levels of cytoplasmic punctae (A), whereas cells
treated with 10 µM AST for 24 hours produced notable punctae in PC3 cells expressing
LC3-EGFP linked protein (B); arrows point to cells expressing pronounced punctae
formation indicative of autophagy induction (B). Untreated PC3 cells stained with
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acridine orange show low level staining (C), whereas PC3 cells treated with 10 µM AST
show significant acridine orange staining in acidic cytoplasmic vesicles. Arrows point to
cells with pronounced acridine-orange-stained granules (orange-red; D). (A-D)
Magnification 400. (E) Immunoblot analysis for autophagy induction measured by LC3
lipidation. 22Rv1 prostate cancer cells were treated with 10 µM AST for 6 hours. An
increase LC3 lipidation by AST is indicative of autophagy modulation (E).

Fig. 4. Radiation and AST induced changes in PC3 prostate cancer cell viability and
cellular fragmentation. (A) MTS cytotoxicity assay of AST and radiation induced cell
death in PC3 cells (n=4; *P<0.05 compared to control). (B) Immunoblot analysis and
quantification of LC3 II protein, a biomarker for the modulation of autophagy in PC3
cells treated with radiation with or without 8 µM AST. (C) Cell fragmentation induced by
AST and radiation treatment in PC3 cells measured by flow cytometry. (D) 10 µM AST
increased cellular fragmentation to 54.4 % (red arrow). (E) Fifteen µM AST increased
cell fragmentation to 76.0 % (red arrow). Cells were gated based on side-scatter (SSC)
and forward-scatter (FSC) patterns. P1 = cell fragmentation gate showing back-ground
levels (red arrow). P2 = non-fragmented % of PC3 cells (blue arrow). (F) Quantification
of cellular fragmentation. Radiation and AST treatment significantly increased
fragmentation (n=3; *P<0.05).
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Table 1 Cell Death Response of AST Combined with Docetaxel or Radiation
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